Research ExplorerPublicationsAGO Recommendations for the Surgical Therapy of the Axilla A...

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update

Standard

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. / Friedrich, Michael; Kühn, Thorsten; Janni, Wolfgang; Müller, Volkmar; Banys-Pachulowski, Maggie; Kolberg-Liedtke, Cornelia; Jackisch, Christian; Krug, David; Albert, Ute-Susann; Bauerfeind, Ingo; Blohmer, Jens; Budach, Wilfried; Dall, Peter; Fallenberg, Eva M; Fasching, Peter A; Fehm, Tanja; Gerber, Bernd; Gluz, Oleg; Hanf, Volker; Harbeck, Nadia; Heil, Jörg; Huober, Jens; Kreipe, Hans-Heinrich; Kümmel, Sherko; Loibl, Sibylle; Lüftner, Diana; Lux, Michael Patrick; Maass, Nicolai; Möbus, Volker; Mundhenke, Christoph; Nitz, Ulrike; Park-Simon, Tjoung-Won; Reimer, Toralf; Rhiem, Kerstin; Rody, Achim; Schmidt, Marcus; Schneeweiss, Andreas; Schütz, Florian; Sinn, Hans-Peter; Solbach, Christine; Solomayer, Erich-Franz; Stickeler, Elmar; Thomssen, Christoph; Untch, Michael; Witzel, Isabell; Wöckel, Achim; Thill, Marc; Ditsch, Nina.

In: GEBURTSH FRAUENHEILK, Vol. 81, No. 10, 10.2021, p. 1112-1120.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Friedrich, M, Kühn, T, Janni, W, Müller, V, Banys-Pachulowski, M, Kolberg-Liedtke, C, Jackisch, C, Krug, D, Albert, U-S, Bauerfeind, I, Blohmer, J, Budach, W, Dall, P, Fallenberg, EM, Fasching, PA, Fehm, T, Gerber, B, Gluz, O, Hanf, V, Harbeck, N, Heil, J, Huober, J, Kreipe, H-H, Kümmel, S, Loibl, S, Lüftner, D, Lux, MP, Maass, N, Möbus, V, Mundhenke, C, Nitz, U, Park-Simon, T-W, Reimer, T, Rhiem, K, Rody, A, Schmidt, M, Schneeweiss, A, Schütz, F, Sinn, H-P, Solbach, C, Solomayer, E-F, Stickeler, E, Thomssen, C, Untch, M, Witzel, I, Wöckel, A, Thill, M & Ditsch, N 2021, 'AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update', GEBURTSH FRAUENHEILK, vol. 81, no. 10, pp. 1112-1120. https://doi.org/10.1055/a-1499-8431

APA

Friedrich, M., Kühn, T., Janni, W., Müller, V., Banys-Pachulowski, M., Kolberg-Liedtke, C., Jackisch, C., Krug, D., Albert, U-S., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Fallenberg, E. M., Fasching, P. A., Fehm, T., Gerber, B., Gluz, O., Hanf, V., ... Ditsch, N. (2021). AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. GEBURTSH FRAUENHEILK, 81(10), 1112-1120. https://doi.org/10.1055/a-1499-8431

Vancouver

Friedrich M, Kühn T, Janni W, Müller V, Banys-Pachulowski M, Kolberg-Liedtke C et al. AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. GEBURTSH FRAUENHEILK. 2021 Oct;81(10):1112-1120. https://doi.org/10.1055/a-1499-8431

Bibtex

@article{47902334bb4b4067b667e14a57272b9c,
title = "AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update",
abstract = "For many decades, the standard procedure to treat breast cancer included complete dissection of the axillary lymph nodes. The aim was to determine histological node status, which was then used as the basis for adjuvant therapy, and to ensure locoregional tumour control. In addition to the debate on how to optimise the therapeutic strategies of systemic treatment and radiotherapy, the current discussion focuses on improving surgical procedures to treat breast cancer. As neoadjuvant chemotherapy is becoming increasingly important, the surgical procedures used to treat breast cancer, whether they are breast surgery or axillary dissection, are changing. Based on the currently available data, carrying out SLNE prior to neoadjuvant chemotherapy is not recommended. In contrast, surgical axillary management after neoadjuvant chemotherapy is considered the procedure of choice for axillary staging and can range from SLNE to TAD and ALND. To reduce the rate of false negatives during surgical staging of the axilla in pN+ CNB stage before NACT and ycN0 after NACT, targeted axillary dissection (TAD), the removal of > 2 SLNs (SLNE, no untargeted axillary sampling), immunohistochemistry to detect isolated tumour cells and micro-metastases, and marking positive lymph nodes before NACT should be the standard approach. This most recent update on surgical axillary management describes the significance of isolated tumour cells and micro-metastasis after neoadjuvant chemotherapy and the clinical consequences of low volume residual disease diagnosed using SLNE and TAD and provides an overview of this year's AGO recommendations for surgical management of the axilla during primary surgery and in relation to neoadjuvant chemotherapy.",
author = "Michael Friedrich and Thorsten K{\"u}hn and Wolfgang Janni and Volkmar M{\"u}ller and Maggie Banys-Pachulowski and Cornelia Kolberg-Liedtke and Christian Jackisch and David Krug and Ute-Susann Albert and Ingo Bauerfeind and Jens Blohmer and Wilfried Budach and Peter Dall and Fallenberg, {Eva M} and Fasching, {Peter A} and Tanja Fehm and Bernd Gerber and Oleg Gluz and Volker Hanf and Nadia Harbeck and J{\"o}rg Heil and Jens Huober and Hans-Heinrich Kreipe and Sherko K{\"u}mmel and Sibylle Loibl and Diana L{\"u}ftner and Lux, {Michael Patrick} and Nicolai Maass and Volker M{\"o}bus and Christoph Mundhenke and Ulrike Nitz and Tjoung-Won Park-Simon and Toralf Reimer and Kerstin Rhiem and Achim Rody and Marcus Schmidt and Andreas Schneeweiss and Florian Sch{\"u}tz and Hans-Peter Sinn and Christine Solbach and Erich-Franz Solomayer and Elmar Stickeler and Christoph Thomssen and Michael Untch and Isabell Witzel and Achim W{\"o}ckel and Marc Thill and Nina Ditsch",
note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",
year = "2021",
month = oct,
doi = "10.1055/a-1499-8431",
language = "English",
volume = "81",
pages = "1112--1120",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "10",

}

RIS

TY - JOUR

T1 - AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update

AU - Friedrich, Michael

AU - Kühn, Thorsten

AU - Janni, Wolfgang

AU - Müller, Volkmar

AU - Banys-Pachulowski, Maggie

AU - Kolberg-Liedtke, Cornelia

AU - Jackisch, Christian

AU - Krug, David

AU - Albert, Ute-Susann

AU - Bauerfeind, Ingo

AU - Blohmer, Jens

AU - Budach, Wilfried

AU - Dall, Peter

AU - Fallenberg, Eva M

AU - Fasching, Peter A

AU - Fehm, Tanja

AU - Gerber, Bernd

AU - Gluz, Oleg

AU - Hanf, Volker

AU - Harbeck, Nadia

AU - Heil, Jörg

AU - Huober, Jens

AU - Kreipe, Hans-Heinrich

AU - Kümmel, Sherko

AU - Loibl, Sibylle

AU - Lüftner, Diana

AU - Lux, Michael Patrick

AU - Maass, Nicolai

AU - Möbus, Volker

AU - Mundhenke, Christoph

AU - Nitz, Ulrike

AU - Park-Simon, Tjoung-Won

AU - Reimer, Toralf

AU - Rhiem, Kerstin

AU - Rody, Achim

AU - Schmidt, Marcus

AU - Schneeweiss, Andreas

AU - Schütz, Florian

AU - Sinn, Hans-Peter

AU - Solbach, Christine

AU - Solomayer, Erich-Franz

AU - Stickeler, Elmar

AU - Thomssen, Christoph

AU - Untch, Michael

AU - Witzel, Isabell

AU - Wöckel, Achim

AU - Thill, Marc

AU - Ditsch, Nina

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

PY - 2021/10

Y1 - 2021/10

N2 - For many decades, the standard procedure to treat breast cancer included complete dissection of the axillary lymph nodes. The aim was to determine histological node status, which was then used as the basis for adjuvant therapy, and to ensure locoregional tumour control. In addition to the debate on how to optimise the therapeutic strategies of systemic treatment and radiotherapy, the current discussion focuses on improving surgical procedures to treat breast cancer. As neoadjuvant chemotherapy is becoming increasingly important, the surgical procedures used to treat breast cancer, whether they are breast surgery or axillary dissection, are changing. Based on the currently available data, carrying out SLNE prior to neoadjuvant chemotherapy is not recommended. In contrast, surgical axillary management after neoadjuvant chemotherapy is considered the procedure of choice for axillary staging and can range from SLNE to TAD and ALND. To reduce the rate of false negatives during surgical staging of the axilla in pN+ CNB stage before NACT and ycN0 after NACT, targeted axillary dissection (TAD), the removal of > 2 SLNs (SLNE, no untargeted axillary sampling), immunohistochemistry to detect isolated tumour cells and micro-metastases, and marking positive lymph nodes before NACT should be the standard approach. This most recent update on surgical axillary management describes the significance of isolated tumour cells and micro-metastasis after neoadjuvant chemotherapy and the clinical consequences of low volume residual disease diagnosed using SLNE and TAD and provides an overview of this year's AGO recommendations for surgical management of the axilla during primary surgery and in relation to neoadjuvant chemotherapy.

AB - For many decades, the standard procedure to treat breast cancer included complete dissection of the axillary lymph nodes. The aim was to determine histological node status, which was then used as the basis for adjuvant therapy, and to ensure locoregional tumour control. In addition to the debate on how to optimise the therapeutic strategies of systemic treatment and radiotherapy, the current discussion focuses on improving surgical procedures to treat breast cancer. As neoadjuvant chemotherapy is becoming increasingly important, the surgical procedures used to treat breast cancer, whether they are breast surgery or axillary dissection, are changing. Based on the currently available data, carrying out SLNE prior to neoadjuvant chemotherapy is not recommended. In contrast, surgical axillary management after neoadjuvant chemotherapy is considered the procedure of choice for axillary staging and can range from SLNE to TAD and ALND. To reduce the rate of false negatives during surgical staging of the axilla in pN+ CNB stage before NACT and ycN0 after NACT, targeted axillary dissection (TAD), the removal of > 2 SLNs (SLNE, no untargeted axillary sampling), immunohistochemistry to detect isolated tumour cells and micro-metastases, and marking positive lymph nodes before NACT should be the standard approach. This most recent update on surgical axillary management describes the significance of isolated tumour cells and micro-metastasis after neoadjuvant chemotherapy and the clinical consequences of low volume residual disease diagnosed using SLNE and TAD and provides an overview of this year's AGO recommendations for surgical management of the axilla during primary surgery and in relation to neoadjuvant chemotherapy.

U2 - 10.1055/a-1499-8431

DO - 10.1055/a-1499-8431

M3 - SCORING: Journal article

C2 - 34629490

VL - 81

SP - 1112

EP - 1120

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 10

ER -